300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
Oil and Gas
InsurTech
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Canada
Liechtenstein
Lebanon
United Kingdom
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Schooner Capital, VC Fund

Schooner Capital

VC Fund

Boston, United States

Schooner Capital is a private investment office. The firm has no outside limited partners and approaches all investments with a long-term perspective.

Total investments:
75
Last investment:
Lead investor:
48%

Last updated:

Industries Schooner Capital invests in

SoftwareBiotechnologyHealth CareInformation TechnologyMedical

Stages Schooner Capital invests in

Funding RoundSeries ASeedSeries BSeries C

Countries Schooner Capital invests in

United StatesIrelandIndiaCanadaIsrael

Round sizes

Seed $1M–$8.5MSeries A $2.3M–$84M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Seed
$1M–$8.5M
Series A
$2.3M–$84M

Investment Focus

Industry

  • Software 12 (16%)
  • Biotechnology 12 (16%)
  • Health Care 10 (13%)
  • Information Technology 8 (11%)
  • Medical 6 (8%)
See all 91 industries →

Stage

  • Funding Round 19 (25%)
  • Series A 13 (17%)
  • Seed 10 (13%)
  • Series B 10 (13%)
  • Series C 5 (7%)
See all 9 stages →

Country

  • United States 39 (52%)
  • Ireland 2 (3%)
  • India 1 (1%)
  • Canada 1 (1%)
  • Israel 1 (1%)
See all 8 countries →

Team

NameTitleInvestmentsLinksEmail
Alexandra Manick
Alexandra Manick Principal
Principal Total investments: 3
Find email
Jake Fiechter
Jake Fiechter Analyst
Analyst Total investments: 0 Find email
Jon Corbett Vice President of Finance
Vice President of Finance Total investments: 0
Find email
Lou Stathis Accountant
Accountant Total investments: 0 Find email
Orhan Gazelle Principal; Managing Director
Principal; Managing Director Total investments: 8
Find email
See all 10 team members →

Investments

CompanyDescriptionRoundLinks
Manna Air Delivery Manna Air Delivery
Manna is a Drone Delivery “As a Service” business. We enable, transform and grow local businesses of all types by powering a 3-minute delivery service across a 30 square mile catchment area for them. Reaching more customers - more quickly and in a more scalable way than road-based delivery.Manna is regulated by the relevant aviation regulatorybodies in Europe and USA. $50M / Series B / Apr 01, 2026
KEWAZO KEWAZO
KEWAZO is digitizing construction with robotics and data analytics. We integrate robotic platforms on-site to enable digital services. In scaffolding, our robotic material hoist LIFTBOT saves up to 44% of labor costs, addresses labor shortage, and improves safety. By having our robots on-site, we collect operational data and provide it to ourcustomers in the form of a data analytics platform, enabling more proactive management of both individual projects and companies overall. $16M / Series A / Mar 19, 2026
Carecubes Carecubes
Carecubes develops medical-grade isolation technology that helps caregivers respond to pandemics in a calm and caring manner. $6.5M / Series A / Mar 19, 2026
Remedy Plan Therapeutics Remedy Plan Therapeutics
Remedy Plan Therapeutics is a pre-clinical-stage company developing small molecule therapeutics to halt tumor growth and disrupt the cancer stem cells that cause metastasis. Our approach is to develop effective, non-toxic treatments that target the dangerous embryonic properties of cancer stem cells, which form the basis for cancer growth, spread,and resistance to chemotherapy. Remedy Plan is positioned to deliver one first-in-class drug candidate for Phase I clinical development approximately 15 months after Series A fundingRemedy Plan's proprietary drug screening platform identifies drug candidates that differentiate cancer stem cells, disrupt proliferation, and inhibit formation of new tumors. From the initial screen of 40,000 drug components, a lead candidate is currently undergoing optimization and mechanism of action studies in preparation for Phase I clinical trials. With the second screen of over 100,000 drug components completed, Remedy Plan aims to have at least two drugs in clinical development by 2020. $18M / Venture - Series Unknown / May 13, 2025
Onebeat Onebeat
Onebeat helps retailers, wholesalers, and brands achieve results through operational optimization. It offers solutions for the needs of the technology of retail. It develops platforms that aim to help businesses optimize how they handle their retail. It's headquarters is in Petach Tikva in Israel and it has branches globally. $15M / May 06, 2025
Onebeat Onebeat
Onebeat helps retailers, wholesalers, and brands achieve results through operational optimization. It offers solutions for the needs of the technology of retail. It develops platforms that aim to help businesses optimize how they handle their retail. It's headquarters is in Petach Tikva in Israel and it has branches globally. $15M / Series C / May 06, 2025
Ottometric Ottometric
Ottometric provides an intelligent verification framework that gives deeper understanding of events and anomalies, helping the industry deliver safer vehicles. The race to get reliable ADAS features to vehicles is speeding up, from driver assistance to full self driving. The industry is investing greatly to innovate. Today, the auto industry isdelivering Level 1 to Level 3 Autonomous capabilities that industry stakeholders have called out as sub-par. $10.3M / Series A / Apr 09, 2025
Meili Meili
Meili is a built technology that allows mobility company to interact with travel partners offering a frictionless consumer experience. $8.5M / Seed / Dec 12, 2024
Mantle Mantle
Mantle is an engineering and manufacturing company that has developed metal 3D printing technology to produce high-resolution parts that meet the critical needs of applications from automotive and aerospace to consumer product design and prototyping. $20M / Series C / Jul 10, 2024
Cartesian Therapeutics Cartesian Therapeutics
Cartesian Therapeutics is a fully integrated, clinical-stage biopharmaceutical company developing novel cell and gene immunotherapies to treat cancer and autoimmune diseases. $130M / Post-IPO Equity / Jul 02, 2024
See all 75 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
Oil and Gas
InsurTech
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Canada
Liechtenstein
Lebanon
United Kingdom
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Schooner Capital invest in?

Schooner Capital invests primarily in Software, Biotechnology and Health Care startups, most often at Funding Round and Series A stage. Most of the 75 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Schooner Capital's check size?

Schooner Capital typically joins rounds of $1M–$8.5M at Seed and $2.3M–$84M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Schooner Capital participates in.

How do I contact Schooner Capital?

Public channels for Schooner Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Schooner Capital?

The team at Schooner Capital includes Alexandra Manick (Principal), Jake Fiechter (Analyst) and Jon Corbett (Vice President of Finance), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Schooner Capital Schooner Capital Find emails